Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : analysts and calls -- ML -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (213)	9/25/2006 7:20:49 PM
From: CapitalistHogg™	Read Replies (1) \| Respond to of 238

Final approval may be contingent on scheduling, which may be proposed by DEA ~2 weeks after the FDA decision. Best case, $35 on approvable, $45 – $50 with Sched 3 or 4 This is the part I believe will make or break the stock price. A true binary event. How does SHPGY fit into all of this? They are showing up on my event based radar and it would be logical that they are connected.

To: tom pope who wrote (213)	12/22/2006 2:01:13 PM
From: tuck	Read Replies (1) \| Respond to of 238

Given this note from September, in which ML calls the value in the best case scenario $45 - $50. Given that this scenario includes a DEA schedule 3 or 4. Given that the stock is well over $50 already, with the DEA yet to rule. And given that the FDA continues to recommend Schedule 2, and that probability of the DEA disagreeing with FDA is less than 50% . . . the note you posted on the TELK thread is just amazing. Message 23124548 They continue to recommend buying in front of the DEA decision in mid-February, even though, by their own numbers there is no reward (unless they have made revisions not disclosed in today's note), and huge risk. Nutty! Very tempted to try my short again. Oh, and they whiffed on their ADLR call, I see. Message 22830930 Cheers, Tuck